entertainment -WSS

entertainment

author：hotspot 2025-08-04 12:29:51 - browse：72

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Patients, doctors press FTC to beef up hospital merger scrutiny

WSS

Grad students accuse University of California of wage theft

How to save health care price transparency rules

People with substance use disorder deserve online privacy

Pushing for an NIH office for post

Transgender sports debate: Physicians say bans are health issue

Pushing for an NIH office for post

entertainment

entertainment

hotspot

Medical leaders decry Supreme Court decision on affirmative action

Acadia's Nuplazid fails as schizophrenia medicine in Phase 3 study

In Memoriam: Notable people who died in 2023

White House Covid adviser calls on docs to combat misinformation

Affirmative action in medical school literally saved lives

FDA panel to weigh safety of artificial wombs for preterm births

After affirmative action ruling, medical educators look to 'holistic review'

'A game

Sports medicine is finally prioritizing gender equality

Patients, doctors press FTC to beef up hospital merger scrutiny

entertainment

Fed up with FDA, ALS advocates consider a take

Boston's new lab space is opening empty

Why the quest to eradicate polio has stumbled

UCLA team creates talking throat patch for voice disorders

Midwives could help bridge maternal health disparities in the U.S.

Patients, doctors press FTC to beef up hospital merger scrutiny

focus

hotspot

knowledge

focus